Scemblix 40mg film-coated tablet Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

scemblix 40mg film-coated tablet

novartis corporation (malaysia) sdn. bhd. - asciminib hydrochloride -

Exjade Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

exjade

novartis pharma stein ag - deferasirox - tablets dispersible - 250mg

Exjade Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

exjade

novartis pharma stein ag - deferasirox - tablets dispersible - 500mg

Surgical procedure kit, ophthalmic, medicated, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

surgical procedure kit, ophthalmic, medicated, single-use

novartis pharmaceuticals australia pty ltd - 46413 - surgical procedure kit, ophthalmic, medicated, single-use - procedure pack containing lucentis vial [aust r 148325] along with a filter needle to be used in ophthalmic procedures.

Medicine administration kit, percutaneous, medicated, single-use Australia - English - Department of Health (Therapeutic Goods Administration)

medicine administration kit, percutaneous, medicated, single-use

novartis pharmaceuticals australia pty ltd - 45156 - medicine administration kit, percutaneous, medicated, single-use - medicine administration kit for sandostatin lar for single use only

TASIGNA 200 MG Israel - English - Ministry of Health

tasigna 200 mg

novartis israel ltd - nilotinib as monohydrate - capsules - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

TASIGNA 150 MG Israel - English - Ministry of Health

tasigna 150 mg

novartis israel ltd - nilotinib as hydrochloride monohydrate - capsules - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

XOLAIR 150 MG Israel - English - Ministry of Health

xolair 150 mg

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

ILARIS 150 MGML Israel - English - Ministry of Health

ilaris 150 mgml

novartis israel ltd - canakinumab - powder for solution for injection - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - ►periodic fever syndromesilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:cryopyrin-associated periodic syndromes (caps)ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including:• muckle-wells syndrome (mws),• neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca),• severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.►tumour necrosis factor receptor associated periodic syndrome (traps)ilaris is indicated for the treatment of tumour necrosis factor (tnf) receptor associated periodic syndrome (traps).►hyperimmunoglobulin d syndrome (hids)/ mevalonate kinase deficiency (mkd)ilaris is i

Trezilent 50mg Film-Coated Tablets Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

trezilent 50mg film-coated tablets

novartis corporation (malaysia) sdn. bhd. - alpelisib -